Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Idogen AB's EV-to-EBIT or its related term are showing as below:
OSTO:IDOGEN's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 16.115 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Idogen AB's Enterprise Value for the quarter that ended in Mar. 2023 was kr5.06 Mil.
Idogen AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-43.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idogen AB EV-to-EBIT Related Terms
Idogen AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Idogen AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IDOGEN vs REGN, VRTX, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Idogen AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idogen AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idogen AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Idogen AB's EV-to-EBIT falls into.
Idogen AB's current Enterprise Value is kr9.60 Mil.
Idogen AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-43.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idogen AB (OSTO:IDOGEN) has a EV-to-EBIT of -0.22 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Idogen AB and its competitors.
Is Idogen AB's EV-to-EBIT too high?
Idogen AB's current EV-to-EBIT is -0.22. Overall, Idogen AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Idogen AB's EV-to-EBIT compare to REGN and VRTX?
Idogen AB's EV-to-EBIT of -0.22 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 16.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.12, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Idogen AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idogen AB's current EV-to-EBIT is -0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idogen AB stock overvalued right now?
Idogen AB (OSTO:IDOGEN) has a current EV-to-EBIT of -0.22. The current EV-to-EBIT is -0.22. Idogen AB's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Idogen AB (OSTO:IDOGEN), the current EV-to-EBIT is -0.22 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
21GF Score
Get the complete analysis for OSTO:IDOGEN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IDOGEN has been successfully added to your 
